Indian CRO taps ArisGlobal to up delivery capabilities

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/fanjianhua)
(Image: Getty/fanjianhua)

Related tags: Clinical trial, Clinical research

SIRO Clinpharm is in “a new area of growth” following the procurement of ArisGlobal’s LifeSphere Clinical platform, which has enabled the company to expand its business prospects, says CRO.

SIRO Clinpharm is a full-service contract research organization (CRO) headquartered in Maharashtra, India.

US-based ArisGlobal’s LifeSphere Clinical platform includes a unified, integrated CTMS and EDC solution, LifeSphere CTMS for Clinical Trial Management, and LifeSphere EDC for Clinical Data Management.

According to SIRO, the platform provides “a comprehensive, versatile and end-to-end clinical research solution​” to its clients.

A company representative told us in a comment that the platform enables SIRO meet database go-live timelines by at least seven working days in advance, “which in turn helps sponsors start and thereby execute a study ahead of pre-determined timelines​.”

These platforms are highly cost effective and give a competitive advantage to our company in terms of delivering a high quality product to our clients within the shortest timeframes​,” they said.

This is a new area of growth wherein the growth of LifeSphere has directly benefited in gaining more business prospects for SIRO​.”

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more